{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:26Z","timestamp":1788516446958,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Object<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate the risk of secondary immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab through a meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched databases including PubMed, Web of Science, OVID and EMBASE for studies reporting changes in platelet levels in MS patients treated with alemtuzumab from their inception until May 2023 and performed a meta-analysis. Information and data were screened and extracted by two researchers. The inclusion and exclusion criteria were established according to the PICOS principle. The obtained data were analyzed using the R software meta package and the quality assessment was conducted using Newcastle-Ottawa Scale (NOS). The causes of heterogeneity were analyzed using subgroup analysis and sensitivity analysis. Publication bias was evaluated using funnel plots and Egger test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 15 studies were included, encompassing 1,729 multiple sclerosis patients. Meta-analysis of overall secondary ITP in the included studies yielded a pooled rate of 0.0243. The overall incidence of secondary autoimmune events was 0.2589. In addition, subgroup analysis was applied using study regions and study types. The results showed that the incidence rate of secondary ITP in Europe was about 0.0207, while the incidence of autoimmune events (AEs) was 0.2158. The incidence rate of secondary ITP and AEs in North America was significantly higher than in Europe, being 0.0352 and 0.2622. And the analysis showed that the incidence rates of secondary ITP and AEs in prospective studies were 0.0391 and 0.1771. Retrospective studies had an incidence rate of secondary ITP at 2.16, and an incidence rate of AEs at 0.2743.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study found that there was a certain incidence of Immune thrombocytopenia in multiple sclerosis patients after treatment with alemtuzumab. Alemtuzumab may have some interference with platelet levels, and the mechanism may be associated with Treg cells. But due to the absence of a control group in the included literature, we cannot determine the specific impact of Alemtuzumab on platelet levels in patients with MS. Therefore, clinical physicians should perform a comprehensive assessment of the patient\u2019s benefit-to-risk ratio before initiating alemtuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      Inplasy website, DOI number is\n                      <jats:ext-link>10.37766\/inplasy2024.3.0007<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1375615","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T01:24:33Z","timestamp":1712712273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of secondary immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"ref1","first-page":"1786","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume-title":"N Engl J Med","author":"Coles","year":"2008"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e00362","DOI":"10.1002\/brb3.362","article-title":"An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis","volume":"5","author":"Garg","year":"2015","journal-title":"Brain Behav"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Mult Scler"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1212\/WNL.0b013e31827b5927","article-title":"Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis","volume":"80","author":"Cossburn","year":"2013","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.nrleng.2019.11.001","article-title":"Consensus statement on the use of alemtuzumab in daily clinical practice in Spain","volume":"37","author":"Meca-Lallana","year":"2022","journal-title":"Neurologia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"ref10","year":"2020"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/14740338.2021.1942454","article-title":"Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies","volume":"20","author":"Buonomo","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Scappaticcio","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ajh.23268","article-title":"Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"87","author":"Reda","year":"2012","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2021.06.007","article-title":"Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim n\u00e1lisis of the LEMVIDA study","author":"Meca-Lallana","year":"2021","journal-title":"Neurologia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"620758","DOI":"10.3389\/fneur.2021.620758","article-title":"Alemtuzumab in a large real-life cohort: interim baseline data of the TREAT-MS study","volume":"12","author":"Ziemssen","year":"2021","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1112193","DOI":"10.3389\/fneur.2023.1112193","article-title":"Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: the RealMS study","volume":"14","author":"Eichau","year":"2023","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1352458517751861","article-title":"2017 McDonald MS diagnostic criteria: evidence-based revisions","volume":"24","author":"Carroll","year":"2018","journal-title":"Mult Scler"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"104030","DOI":"10.1016\/j.msard.2022.104030","article-title":"Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen","volume":"66","author":"Leckey","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00415-021-10664-w","article-title":"Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients","volume":"269","author":"Rauma","year":"2022","journal-title":"J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"102717","DOI":"10.1016\/j.msard.2020.102717","article-title":"Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8 years","volume":"49","author":"Bass","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/acn3.51366","article-title":"aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis","volume":"8","author":"H\u00e4u\u00dfler","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1007\/s10072-021-05145-x","article-title":"Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study","volume":"42","author":"Brecl Jakob","year":"2021","journal-title":"Neurol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"102945","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1111\/ene.15054","article-title":"Alemtuzumab in multiple sclerosis: a retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors","volume":"28","author":"Bachmann","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"101504","DOI":"10.1016\/j.msard.2019.101504","article-title":"Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center","volume":"38","author":"di Ioia","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/ene.14324","article-title":"Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab","volume":"27","author":"Boffa","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.msard.2019.01.019","article-title":"Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)","volume":"29","author":"Vukusic","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/1352458518783673","article-title":"Successful implementation of an automated electronic support system for patient safety monitoring: the alemtuzumab in multiple sclerosis safety systems (AMS3) study","volume":"25","author":"Reddel","year":"2019","journal-title":"Mult Scler"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/acn3.50935","article-title":"Impact of Fc\u03b3R variants on the response to alemtuzumab in multiple sclerosis","volume":"6","author":"Keller","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1468-1331.2011.03507.x","article-title":"A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis","volume":"19","author":"Fox","year":"2012","journal-title":"Eur J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3389\/fimmu.2019.01204","article-title":"Alemtuzumab in multiple sclerosis: short- and long-term effects of immunodepletion on the peripheral treg compartment","volume":"10","author":"Haas","year":"2019","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood-2012-02-413526","article-title":"Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia","volume":"120","author":"Aslam","year":"2012","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3 regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/vcp.12774","article-title":"Immune thrombocytopenia (ITP): pathophysiology update and diagnostic dilemmas","volume":"48","author":"LeVine","year":"2019","journal-title":"Vet Clin Pathol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J Neuroinflammation"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1212\/NXI.0000000000000635","article-title":"Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab","volume":"7","author":"Wiendl","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"678355","DOI":"10.3389\/fimmu.2021.678355","article-title":"The alterations in and the role of the Th17\/Treg balance in metabolic diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.18303","article-title":"Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia","volume":"198","author":"Pedersen","year":"2022","journal-title":"Br J Haematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1352458518816612","article-title":"Immune thrombocytopenia in alemtuzumab-treated MS patients: incidence, detection, and management","volume":"26","author":"Cuker","year":"2020","journal-title":"Mult Scler"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/j.1538-7836.2012.04876.x","article-title":"Contemporary management of primary immune thrombocytopenia in adults","volume":"10","author":"Lakshmanan","year":"2012","journal-title":"J Thromb Haemost"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13760-018-0882-3","article-title":"Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus","volume":"118","author":"Lambert","year":"2018","journal-title":"Acta Neurol Belg"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1375615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T01:24:38Z","timestamp":1712712278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1375615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":46,"alternative-id":["10.3389\/fneur.2024.1375615"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1375615","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"article-number":"1375615"}}